Ozempic unboxing videos: what TikTok gets right and wrong

What did @maggiecortezsv actually say?

Honestly? Not much. The transcript is almost entirely a background song, repeated phrases like "check it out" and "go, go, go," and ends with "I gotta go now." The caption does the heavy lifting: it describes Ozempic as "a medication to control type 2 diabetes" that was "recently approved by the FDA to lose weight" and frames the video as a guide to what's inside the box and how to use it.

So the actual spoken content here is essentially zero. Whatever instructional information @maggiecortezsv delivered about Ozempic was visual, not verbal. That matters for a fact-check because we can only evaluate what's verifiable. The caption claims are what we can actually work with, and they're worth examining closely given this video has 1.1 million views.

Does the science back this up?

The caption's core claims are accurate in broad strokes, but they compress a complicated regulatory and clinical history in ways that could mislead viewers.

Semaglutide, the active ingredient in Ozempic, was approved by the FDA for type 2 diabetes management in December 2017 (Ozempic, Novo Nordisk). That part checks out. The weight loss approval claim is also directionally correct, but the framing is sloppy. Wegovy, a higher-dose semaglutide formulation, received FDA approval for chronic weight management in June 2021. Ozempic itself has never been FDA-approved for weight loss. Wilding et al. (2021, New England Journal of Medicine) published the STEP 1 trial showing 14.9% mean body weight reduction with semaglutide 2.4 mg over 68 weeks, which was the basis for Wegovy's approval, not Ozempic's label.

These are two different products with different approved indications, and conflating them is a recurring problem in GLP-1 social media content. It's not a small distinction.

What did they get wrong (or right)?

Credit where it's due: calling Ozempic a medication for type 2 diabetes is accurate. Saying it has become very popular is an understatement, so that's fine.

The problem is the implied equivalency between Ozempic and FDA-approved weight loss treatment. Ozempic is widely prescribed off-label for weight loss, and that practice is legal. But "recently approved by the FDA to lose weight" is inaccurate as applied to Ozempic specifically. Wegovy carries that indication. Davies et al. (2021, Lancet) confirmed semaglutide's weight management efficacy but in the context of Wegovy's dosing schedule, not Ozempic's.

If a viewer walks away thinking Ozempic is an FDA-approved weight loss drug, that's a meaningful misunderstanding. It affects how they might discuss it with a doctor, how they interpret their insurance coverage, and whether they understand that their prescriber is working off-label. The caption deserved more precision for a video with over a million views.

What should you actually know?

Here is what the caption should have said, or what any viewer should understand before asking a doctor about semaglutide:

• Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) is FDA-approved for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
• Wegovy (semaglutide 2.4 mg) is the formulation FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition.
• Off-label prescribing of Ozempic for weight loss is common and legal, but it is not the same as using an FDA-approved weight loss drug.
• Compounded semaglutide is not equivalent to brand-name Ozempic or Wegovy. The FDA has warned that compounded versions lack the same safety and efficacy data.
• Side effects are real and common. Nausea, vomiting, and gastrointestinal symptoms affect a significant portion of users. Knop et al. (2023, Lancet) documented these in structured trial settings.

None of this means semaglutide is dangerous or ineffective. The clinical evidence is strong. But a 1.1 million-view video about "what's in the box and how to use it" carries real-world consequence, and the caption sets up a frame that isn't quite right.

Bottom line

The caption gets the general story in the right zip code but lands on the wrong block. Ozempic is not FDA-approved for weight loss. Wegovy is. They share an active ingredient at different doses. Mixing them up in a video this widely viewed is the kind of casual inaccuracy that compounds across millions of impressions and creates genuine confusion when patients sit down with their doctors. The unboxing content itself is impossible to evaluate from the transcript alone, but the framing around it needs a correction.